Infographic | April 13, 2022

Preference Among Users – New & Emerging Biopharma

Source: ISR Reports

In Q32021, ISR asked new & emerging biopharma respondents (those with R&D <$500M) which CDMOs they are currently working with, and if the choice were entirely up to them, which CDMO would they prefer to use for all biologic drug substance manufacturing. The data show Catalent and Lonza are the preferred CDMO among nearly roughly of their new & emerging biopharma users. Patheon follows, as the preferred CDMO among one-third of new & emerging biopharma users included in the survey. This poses a threat to smaller CDMOs that want to win virtual biopharma business and is a sign that the CDMO giants are effectively adapting the the needs of this customer group. To learn more about CDMO preference among users, follow the link to the Biologic API CDMO Benchmarking report preview.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online